Grace Therapeutics, Inc. Operating Lease Right-of-Use Assets
Grace Therapeutics, Inc. (GRCE) had Operating Lease Right-of-Use Assets of $0 as of 2024-03-31, per its 10-K filed 2024-06-21.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2024-06-21
- 2024-03-31: Operating Lease, Right-of-Use Asset $0.00.
- 2023-12-31: Operating Lease, Right-of-Use Asset $23.00K.
- 2023-09-30: Operating Lease, Right-of-Use Asset $47.00K.
- 2023-06-30: Operating Lease, Right-of-Use Asset $71.00K.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2024-03-31 | $0.00 10-K · filed 2024-06-21 |
| 2023-12-31 | $23.00K 10-Q · filed 2024-02-12 |
| 2023-09-30 | $47.00K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $71.00K 10-Q · filed 2023-08-11 |
| 2023-03-31 | $463.00K 10-K · filed 2024-06-21 |
| 2022-12-31 | $487.00K 10-Q · filed 2023-02-14 |
| 2022-09-30 | $510.00K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $819.00K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $315.00K 10-K · filed 2023-06-23 |
| 2021-12-31 | $22.00K 10-Q · filed 2022-02-14 |
| 2021-09-30 | $43.00K 10-Q · filed 2021-11-10 |
| 2021-06-30 | $66.00K 10-Q · filed 2021-08-12 |
| 2021-03-31 | $86.00K 10-K · filed 2022-06-21 |
| 2020-12-31 | $105.00K 10-Q · filed 2021-02-09 |
| 2020-09-30 | $119.00K 10-Q · filed 2020-11-16 |
| 2020-06-30 | $135.00K 10-Q · filed 2020-08-13 |
| 2020-03-31 | $147.00K 10-K · filed 2021-06-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |